Loading...

About Us

 We are a privately-held biotechnology company located in Huntersville, North Carolina focused on Cancer Immunotherapy.

Contract Services

We collaborate with industry leaders by contributing to translational research, biospecimen banking and procurement, & cell manufacturing.

Clinical Trials

Our expert Providers participate in national clinical trials to advance cancer immunotherapy research and to help bring novel therapies to patients.

Science + Pipeline

Our portfolio of nonclinical cell therapy programs leverages the intrinsic specificity of autologous immune cells to potentially treat solid tumors.

*Patient infusion of cell therapy products not currently performed.

These products and their uses are investigational and have not been proven to be safe or been approved by the U.S. Food and Drug Administration (FDA).

View Our Facilities

In The News

Unlocking The Common Issues of Cancer Therapies – featuring Dr. John Powderly

One Cancer Place

Title21 Customer Spotlight: Carolina BioOncology Institute

Title21 Health Solutions

Featured Practice: Carolina BioOncology Institute & BioCytics Human Applications Lab

Charlotte Mag Content Studio

Highlights from the September 9th Event UNC Charlotte Dubois Center Through NCBiotech

The Center for Biomedical Engineering and Science

National Minority Quality Forum’s announces a collaboration with Carolina BioOncology Institute

NMQF By Adjoa Kyerematen

NMQF, Carolina BioOncology, and BioCytics are collaborating to create a national registry and biorepository for CSSI, collecting critical clinical, genetic, and demographic data from 20 communities. This biorepository will support research on cancer risk factors, driving logistical changes to ease the development and deployment of new detection technologies and precision treatments. De-identified data will be accessible to researchers, helping ensure that advancements in cancer care reach underserved communities. The findings will be used to improve local cancer care logistics, advancing the Cancer Moonshot’s goal of reducing cancer mortality in these populations by addressing bottlenecks through a data-driven approach.

Expanding Cellular Therapies in a Community Setting: An Interview with Dr. John Powderly, II

Biomedical Sciences Symposium 2024

Dr. John Powderly II, Medical Oncologist, Certified Physician Investigator, and Founder and President of Carolina BioOncology Institute and BioCytics, realized early on in his medical career that he felt a strong passion for cellular therapies. As a 4th year medical student interning under the mentorship of immunotherapy pioneer Dr. Steven Rosenberg at the National Cancer Institute, Dr. Powderly first started working with cellular therapies in the mid-1990s and has since dedicated his career to this therapeutic area. Shortly after completing his oncology fellowship at University of North Carolina, Chapel Hill, Dr. Powderly founded the Carolina BioOncology Institute (CBOI) in 2005 as a community-based clinic specializing in early phase immunotherapy and cellular therapy trials. Located in Charlotte, North Carolina, CBOI is the only independent phase I cancer center with cellular manufacturing capabilities on the east coast and serves as a regional hub for access to phase I trials in the community setting.